Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session today at Heart Failure 2026, the annual congress of the Heart ...
Placebo-controlled evidence across 9013 patients showed a lower composite risk (HR 0.85) driven by reduced worsening HF events rather than any detectable mortality benefit. Worsening HF events were ...
A low dose of digoxin ensures that people with heart failure are hospitalized and die less frequently. This emerges from three studies led by UMCG cardiologists Dirk Jan van Veldhuisen, Kevin Damman, ...
Heart failure (HF) patients who have reduced or mildly reduced ejection fraction derive better outcomes when low-dose digoxin ...
Digoxin, a cardiac glycoside derived from the foxglove plant, has been a mainstay of treatment in systolic heart failure and in rate control for atrial fibrillation. By inhibiting the cardiac ...
Heart drugs called digitalis glycosides, which include digoxin and digitoxin, have been used for centuries, but their place in the modern treatment of heart failure remains undefined. Results were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results